UNCY

Unicycive Therapeutics: FDA Grants Orphan Drug Designation To UNI-494

(RTTNews) - Unicycive Therapeutics, Inc. (UNCY) announced the FDA has granted orphan drug designation to UNI-494 for the prevention of Delayed Graft Function in kidney transplant patients. On March 12, 2024, the company will present data on the efficacy of UNI-494 in animal models of Delayed Graft Function and a poster describing the ongoing Phase 1 clinical trial design for UNI-494 in healthy volunteers at the 29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024.

Shalabh Gupta, CEO of Unicycive, said: "Obtaining orphan drug designation is an important milestone in the development of UNI-494 that may provide certain tax credits for qualified clinical trials, exemption of user fees, and the potential for seven years of market exclusivity after approval."

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.